Sheremata William A, Jy Wenche, Delgado Sylvia, Minagar Alireza, McLarty Jerry, Ahn Yeon
Department of Neurology, Leonard Miller School of Medicine, University of Miami, Miami, Florida, USA.
J Neuroinflammation. 2006 Sep 4;3:23. doi: 10.1186/1742-2094-3-23.
A correlation between plasma CD31+ endothelial microparticles (CD31+EMP) levels and clinical, as well as brain MRI activity, in multiple sclerosis (MS) patients has been previously reported. However, the effect(s) of treatment with interferon-beta1a (IFN-beta1a) on plasma levels of CD31+EMP has not been assessed. In a prospective study, we measured plasma CD31+EMP levels in 30 patients with relapsing-remitting MS.
Using flow cytometry, in a blinded study, we measured plasma CD31+EMP in 30 consecutive patients with relapsing-remitting MS (RRMS) prior to and 4, 12, 24 and 52 weeks after initiation of intramuscular therapy with interferon-beta1a (IFN-beta1a), 30 micrograms weekly. At each visit, clinical examination was performed and expanded disability status scale (EDSS) scores were assessed.
Plasma levels of CD31+EMP were significantly reduced from 24 through 52 weeks following initiation of treatment with IFN-beta1a.
Our data suggest that serial measurement of plasma CD31+EMP levels may be used as a surrogate marker of response to therapy with INF-beta1a. In addition, the decline in plasma levels of CD31+EMP further supports the concept that IFN-beta1a exerts stabilizing effect on the cerebral endothelial cells in pathogenesis of MS.
先前已有报道称，多发性硬化症（MS）患者的血浆CD31 +内皮微粒（CD31 + EMP）水平与临床症状以及脑部MRI活动之间存在相关性。然而，尚未评估β-干扰素1a（IFN-β1a）治疗对血浆CD31 + EMP水平的影响。在一项前瞻性研究中，我们测量了30例复发缓解型MS患者的血浆CD31 + EMP水平。
在一项盲法研究中，我们使用流式细胞术，在30例连续复发缓解型MS（RRMS）患者中，于肌肉注射30μg/周的β-干扰素1a（IFN-β1a）治疗前以及治疗后4、12、24和52周测量血浆CD31 + EMP。每次就诊时均进行临床检查并评估扩展残疾状态量表（EDSS）评分。
开始使用IFN-β1a治疗后24周至52周，血浆CD31 + EMP水平显著降低。
我们的数据表明，连续测量血浆CD31 + EMP水平可作为对INF-β1a治疗反应的替代标志物。此外，血浆CD31 + EMP水平的下降进一步支持了IFN-β1a在MS发病机制中对脑内皮细胞具有稳定作用的概念。
Zotero 插件